Silo Pharma Incの企業情報（従業員数・代表者名など）
最終更新
特色
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
| 英文社名 | Silo Pharma Inc |
|---|---|
| 本社所在地 | 677 N Washington Blvd SARASOTA, FL 34236 USA |
| 電話番号 | --- |
| 設立年月 | 2023年12月 |
| 代表者名 | Eric Weisblum |
| 業種名 | 医療関連（Health Care） |
| 市場名 | --- |
| 従業員数 | --- |
| ウェブサイト | https://silopharma.com/ |
企業の強みが業績にどのように表れているか、業績情報よりご確認いただけます。
業績情報を見る